Cargando…

Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study

BACKGROUND: Cancer and sepsis share risk factors, and sepsis patients may have impaired immune response and increased morbidity long after intensive care. This study aimed to assess whether sepsis survivors are at increased risk for cancer. Our objective was to assess the incidence of new cancer in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hästbacka, Johanna, But, Anna, Strandberg, Gunnar, Lipcsey, Miklós
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543324/
https://www.ncbi.nlm.nih.gov/pubmed/37773171
http://dx.doi.org/10.1186/s13054-023-04654-9
_version_ 1785114276931829760
author Hästbacka, Johanna
But, Anna
Strandberg, Gunnar
Lipcsey, Miklós
author_facet Hästbacka, Johanna
But, Anna
Strandberg, Gunnar
Lipcsey, Miklós
author_sort Hästbacka, Johanna
collection PubMed
description BACKGROUND: Cancer and sepsis share risk factors, and sepsis patients may have impaired immune response and increased morbidity long after intensive care. This study aimed to assess whether sepsis survivors are at increased risk for cancer. Our objective was to assess the incidence of new cancer in 1-year sepsis survivors and test the hypothesis that it is higher than that of the general population. METHODS: We obtained data on ICU admissions of adult patients from Swedish Intensive care registry (SICR) from 2005 to 2017. We included patients with an explicit ICD-10 code for sepsis for the primary ICU admission. We obtained data on cancer diagnoses (2001–2018), death (2005–2018) and emigration (2005–2018) from Cancer and Cause of death and National Patient Registry databases of the National Board of Health and Welfare; age and sex-specific cancer incidence rates in Sweden from NORDCAN registry from 2006 to 2018. One-year survivors formed the final cohort, that was followed for new cancer diagnoses until death, emigration, or end of 2018, whichever came first. The main outcome measure was standardized incidence rate ratio (SIR) to compare the incidence of cancer in 1-year sepsis survivors to that in the general population (NORDCAN). We also performed several sensitivity analyses. RESULTS: In a cohort of 18,550 1-year survivors, 75,427 person years accumulated during a median follow-up (FU) of 3.36 years (IQR 1.72–5.86), 6366 (34.3%) patients died, and 1625 (8.8%) patients were diagnosed with a new cancer after a median FU of 2.51 (IQR 1.09–4.48) years. The incidence ratio of any new cancer over the whole FU was 1.31 (95% CI 1.23–1.40) for men and 1.74 (95% CI 1.61–1.88) for women. The difference in incidence rates persisted in several sensitivity analyses. The SIRs were highest in cancers of gastrointestinal tract, genital organs, and skin. CONCLUSION AND RELEVANCE: Compared to general population, incidence of cancer is increased in 1-year sepsis survivors. Variation in the findings depending on follow-up time suggests that factors other than sepsis alone are involved. Surveillance for malignant disease may be warranted in sepsis survivors. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-023-04654-9.
format Online
Article
Text
id pubmed-10543324
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105433242023-10-03 Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study Hästbacka, Johanna But, Anna Strandberg, Gunnar Lipcsey, Miklós Crit Care Research BACKGROUND: Cancer and sepsis share risk factors, and sepsis patients may have impaired immune response and increased morbidity long after intensive care. This study aimed to assess whether sepsis survivors are at increased risk for cancer. Our objective was to assess the incidence of new cancer in 1-year sepsis survivors and test the hypothesis that it is higher than that of the general population. METHODS: We obtained data on ICU admissions of adult patients from Swedish Intensive care registry (SICR) from 2005 to 2017. We included patients with an explicit ICD-10 code for sepsis for the primary ICU admission. We obtained data on cancer diagnoses (2001–2018), death (2005–2018) and emigration (2005–2018) from Cancer and Cause of death and National Patient Registry databases of the National Board of Health and Welfare; age and sex-specific cancer incidence rates in Sweden from NORDCAN registry from 2006 to 2018. One-year survivors formed the final cohort, that was followed for new cancer diagnoses until death, emigration, or end of 2018, whichever came first. The main outcome measure was standardized incidence rate ratio (SIR) to compare the incidence of cancer in 1-year sepsis survivors to that in the general population (NORDCAN). We also performed several sensitivity analyses. RESULTS: In a cohort of 18,550 1-year survivors, 75,427 person years accumulated during a median follow-up (FU) of 3.36 years (IQR 1.72–5.86), 6366 (34.3%) patients died, and 1625 (8.8%) patients were diagnosed with a new cancer after a median FU of 2.51 (IQR 1.09–4.48) years. The incidence ratio of any new cancer over the whole FU was 1.31 (95% CI 1.23–1.40) for men and 1.74 (95% CI 1.61–1.88) for women. The difference in incidence rates persisted in several sensitivity analyses. The SIRs were highest in cancers of gastrointestinal tract, genital organs, and skin. CONCLUSION AND RELEVANCE: Compared to general population, incidence of cancer is increased in 1-year sepsis survivors. Variation in the findings depending on follow-up time suggests that factors other than sepsis alone are involved. Surveillance for malignant disease may be warranted in sepsis survivors. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-023-04654-9. BioMed Central 2023-09-29 /pmc/articles/PMC10543324/ /pubmed/37773171 http://dx.doi.org/10.1186/s13054-023-04654-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hästbacka, Johanna
But, Anna
Strandberg, Gunnar
Lipcsey, Miklós
Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study
title Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study
title_full Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study
title_fullStr Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study
title_full_unstemmed Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study
title_short Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study
title_sort risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543324/
https://www.ncbi.nlm.nih.gov/pubmed/37773171
http://dx.doi.org/10.1186/s13054-023-04654-9
work_keys_str_mv AT hastbackajohanna riskofmalignantdiseasein1yearsepsissurvivorsaregistrybasednationwidefollowupstudy
AT butanna riskofmalignantdiseasein1yearsepsissurvivorsaregistrybasednationwidefollowupstudy
AT strandberggunnar riskofmalignantdiseasein1yearsepsissurvivorsaregistrybasednationwidefollowupstudy
AT lipcseymiklos riskofmalignantdiseasein1yearsepsissurvivorsaregistrybasednationwidefollowupstudy